Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells

Nutrition and Cancer

Volumn 63, Issue 7, 2011, Pages 1133-1142

  Pathi, Satya S ^a   Lei, Ping ^b   Sreevalsan, Sandeep ^a   Chadalapaka, Gayathri ^a   Jutooru, Indira ^a   Safe, Stephen ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTATHIONE; GLYCOPROTEIN; HYDROGEN PEROXIDE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PREGNANCY SPECIFIC BETA3 GLYCOPROTEIN; PREGNANCY SPECIFIC BETA4 GLYCOPROTEIN; PROTEIN BCL 2; SCATTER FACTOR RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; COLON CANCER; DOWN REGULATION; GENE CONTROL; HUMAN; HUMAN CELL;

ANTICARCINOGENIC AGENTS; ASCORBIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MET; REACTIVE OXYGEN SPECIES; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; SP4 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80053630206     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2011.605984     Document Type: Article

References (48)

1. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, et al.: Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 22, 18-35, 2003. (Pubitemid 36164454)
2. Verrax J and Calderon PB: The controversial place of vitamin C in cancer treatment. Biochem Pharmacol 76, 1644-1652, 2008.
3. Levine M, Espey MG, and Chen Q: Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic Biol Med 47, 27-29, 2009.
4. Cameron E and Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73, 3685-3689, 1976.
5. Cameron E and Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75, 4538-4542, 1978. (Pubitemid 9028392)
6. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301, 687-690, 1979. (Pubitemid 10240445)
7. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, et al.: Highdose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 137-141, 1985. (Pubitemid 15192859)
8. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, et al.: Cyto-toxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 84, 1544-1550, 2001. (Pubitemid 32579348)
9. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105, 11105-11109, 2008.
10. Park CH, Amare M, Savin MA, and Hoogstraten B: Growth suppression of human leukemic cells in vitro by L-ascorbic acid. Cancer Res 40, 1062-1065, 1980. (Pubitemid 10135808)
11. De Laurenzi V, Melino G, Savini I, Annicchiarico-Petruzzelli M, Finazzi-Agro A, et al.: Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. Eur J Cancer 31A, 463-466, 1995.
12. Prasad KN, Sinha PK, Ramanujam M, and Sakamoto A: Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 76, 829-832, 1979. (Pubitemid 9130954)
13. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, et al.: Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 39, 649-657, 2005. (Pubitemid 40846837)
14. Verrax J and Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47, 32-40, 2009.
15. Ohno S, Ohno Y, Suzuki N, Soma G, and Inoue M: High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 29, 809-815, 2009.
16. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, et al.: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J 27, 7-19, 2008.
17. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, et al.: Pharma-cologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102, 13604-13609, 2005. (Pubitemid 41420895)
18. Duarte TL, Almeida GM, and Jones GD: Investigation of the role of extracellular H2O2 and transition metal ions in the genotoxic action of ascorbic acid in cell culture models. Toxicol Lett 170, 57-65, 2007. (Pubitemid 46498905)
19. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, et al.: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104, 8749-8754, 2007. (Pubitemid 47175383)
20. Hu J, Fang J, Dong Y, Chen SJ, and Chen Z: Arsenic in cancer therapy. Anticancer Drugs 16, 119-127, 2005. (Pubitemid 40250606)
21. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, et al.: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR α protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90, 124-133, 1998. (Pubitemid 28114413)
22. Miller WH Jr., Schipper HM, Lee JS, Singer J, and Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 62, 3893-3903, 2002. (Pubitemid 34792653)
23. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, et al.: Arsenic trioxide downregulation of specificity protein (Sp) transcription factors in bladder cancer cells is dependent on reactive oxygen species (ROS). Exper Cell Res 316, 2174-2188, 2010.
24. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R III, et al.: Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68, 5345-5354, 2008.
25. Chadalapaka G, Jutooru I, Burghardt R, and Safe S: Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8, 739-750, 2010.
26. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Abudayyeh A, et al.: Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3, 11-dioxo-18β-olean-1, 12-dien-30-oate in colon cancer cells. Int J Cancer 125, 1965-1974, 2009.
27. Lee YJ and Shacter E: Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 274, 19792-19798, 1999.
28. Lee YJ and Shacter E: Hydrogen peroxide inhibits activation, not activity, of cellular caspase-3 in vivo. Free Radic Biol Med 29, 684-692, 2000.
29. Abdelrahim M and Safe S: Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expession in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 68, 317-329, 2005. (Pubitemid 41058295)
30. Abdelrahim M, Samudio I, Smith R, Burghardt R, and Safe S: Small inhibitory RNA duplexes for Sp1 mRNA block basal and estrogen-induced gene expression and cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 277, 28815-28822, 2002.
31. Abdelrahim M, Smith R III, Burghardt R, and Safe S: Role of Sp proteins in regulationofvascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64, 6740-6749, 2004. (Pubitemid 39297937)
32. Higgins KJ, Abdelrahim M, Liu S, Yoon K, and Safe S: Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem Biophys Res Commun 345, 292-301, 2006. (Pubitemid 44269283)
33. Bouwman P and Philipsen S: Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195, 27-38, 2002. (Pubitemid 35287159)
34. Black AR, Black JD, and Azizkhan-Clifford J: Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188, 143-160, 2001. (Pubitemid 32622905)
35. Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41, 2438-2448, 2005. (Pubitemid 41540621)
36. Dynan WS and Tjian R: The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 35, 79-87, 1983. (Pubitemid 14240221)
37. Ammendola R, Mesuraca M, Russo T, and Cimino F: Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 267, 17944-17948, 1992.
38. Adrian GS, Seto E, Fischbach KS, Rivera EV, Adrian EK, et al.: YY1 and Sp1 transcription factors bind the human transferrin gene in an age-related manner. J Gerontol A Biol Sci Med Sci 51, B66-B75, 1996. (Pubitemid 26026965)
39. Oh JE, Han JA, and Hwang ES: Downregulation of transcription factor, Sp1, during cellular senescence. Biochem Biophys Res Commun 353, 86-91, 2007. (Pubitemid 46001376)
40. 2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 67, 11001-11011, 2007. (Pubitemid 350145930)
41. Chintharlapalli S, Papineni S, Ramaiah SK, and Safe S: Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67, 2816-2823, 2007. (Pubitemid 46548971)
42. Abdelrahim M, Baker CH, Abbruzzese JL, and Safe S: Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98, 855-868, 2006. (Pubitemid 43923442)
43. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, et al.: Downregulation of overexpressed Sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65, 1007-1017, 2005. (Pubitemid 40216463)
44. Kumar S, Sun X, Wiseman DA, Tian J, Umapathy NS, et al.: Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of Sp1 activity. DNA Cell Biol 28, 119-129, 2009.
45. Wang X, Wang J, Lin S, Geng Y, Wang J, et al.: Sp1 is involved in H2O2-induced PUMA gene expression and apoptosis in colorectal cancer cells. J Exp Clin Cancer Res 27, 44, 2008.
46. Chu S and Ferro TJ: Identification of a hydrogen peroxide-induced PP1-JNK1-Sp1 signaling pathway for gene regulation. Am J Physiol Lung Cell Mol Physiol 291, L983-L992, 2006. (Pubitemid 44772061)
47. Dasari A, Bartholomew JN, Volonte D, and Galbiati F: Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66, 10805-10814, 2006. (Pubitemid 44876976)
48. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, et al.: Sp1 and Sp3 are ox-idative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 23, 3597-3606, 2003. (Pubitemid 36958467)